Slide 1: Dong-A ST 2013 Performance Results
Dong-A ST 2013 Performance Results MAY 2013 All of us at Dong-A ar icated to building a heathler society for humanity. Thia philosophy encompasses the health and well- being of humankind as a whole as well as the environment and the vormy. Committed to building a healthier aociety for all, we collab
Slide 2: Pro-forma results and forward-looking statement notice
The business results for the 1st quarter of 2013, currently under audit review, are presented here as pro-forma for investors’ convenience. Hence, please be advised that some of their contents may be altered in the course of audit. This presentation may contain “forward-looking statement.” Forecasts
Slide 3: Agenda
I. 1Q 2013 Performance II. Dong-A ST Performance by Division III. Dong-A Pharm. Performance by Division IV. Current Issues Appendix 2
Slide 4: I. 1Q 2013 Performance
I. 1Q 2013 PERFORMANCE W Donc-a ST
Slide 5: Sales, COGS, SG&A Expenses
[KRW bil.] Dong-A ST 1Q before Demerger** March 2013 1Q 2013 (Pro-forma) (Pro-forma) Sales 47.9 146.9 **215.6 COGS 21.8 66.0 **99.9 SG&A Expenses 22.7 66.3 103.0 HR Related Cost 7.9 20.9 31.7 R&D Cost 4.8 14.4 22.1 Advertisement Cost 0.8 1.8 9.0 Other Marketing Related Cost 3.9 13.5 14.6 Operating P
Slide 6: Sales and Operating Profit YoY and QoQ
YoY QoQ [KRW bil.] [KRW bil.] 27.4 (12.3%) 14.1 (6.5%) 12.7 (5.9%) 12.7 (5.9%) 218.6 -1.4% 215.6 222.7 -3.2% 215.6 1Q '12 1Q '13 4Q '12 1Q '13 Sales OP (OPM) 5
Slide 7: Sales by division: 1Q12, 4Q12, 1Q13
1Q 12 4Q 12 1Q 13 YoY QoQ Dong-A ST ETC 107.7 106.3 98.7 -8.4% -7.1% Export 21.6 22.4 28.5 32.0% 27.0% Medical 20.6 17.9 16.2 -21.1% -9.6% Other 2.7 3.5 4.1 51.3% 16.9% Total 152.5 150.1 147.5 -3.3% -1.7% Dong-A Pharm. Bacchus 32.7 37.2 33.6 2.7% -9.8% OTC 33.3 35.4 34.7 4.1% -2.0% Total 66.0 72.6 6
Slide 8: II. Dong-A ST Performance by Division
Il, DONG-A ST PERFORMANCE BY DIVISION W Donc-a ST
Slide 9: ETC and Major ETC Products
ETC (YoY, QoQ) Major ETC Products (YoY) [KRW bil.] [KRW bil.] -17.2% 21.0 17.3 -20.4% -0.6% -7.3% 8.7% 8.1 7.5 7.5 226.1% 6.4 6.1 5.6 5.6 6.1 4.7 1.5 Stillen Plavitor Lipinon Opalmon Growtropin Motilitone 107.7 106.3 -8.4% -7.1% 98.7 1Q '12 1Q '13 -5.6% -42.7% -12.1% 5.6 5.3 -3.0% -13.8% 5.0 4.9 4.3
Slide 10: Export and Major Regions & Products
Export (YoY, QoQ) Major Regions & Products (YoY) [KRW bil.] [KRW bil.] 72.3% 8.9 89.9% 2.8% 6.2 5.7 5.9 5.2 35.0% 3.3 3.4 2.5 -59.8% -15.5% 1.6 0.6 1.0 0.8 Growtropin Cycloserine Terizidone Atorvastatin Zydena Bacchus 28.5 92.5% 32.0% 27.0% 1Q '12 1Q '13 21.6 22.4 80.5% 8.3 5.9 -5.5% 4.8 4.6 4.3 36.
Slide 11: Medical and Major Medical Products
Medical (YoY, QoQ) Major Medical Products (YoY) [KRW bil.] [KRW bil.] 20.6 -21.1% 13.6% 5.8 17.9 -9.6% 5.1 16.2 11.0 Medical -0.7% 12.0 -11.5% Equipment 11.0 -8.5% 2.4 2.1 -14.1% -32.7% -8.9% 1.5 Diagnosis 1.2 1.3 1.1 1.0 0.8 9.5 -44.8% 5.3 -11.9% 6.0 Artificial Blood Prosthetic Dental Surgical Join
Slide 12: III. Dong-A Pharm. Performance by Division
W Donc-a ST lil, DONG-A PHARM. PERFORMANCE BY DIVISION 11
Slide 13: Bacchus and Bacchus D & F
Bacchus (YoY, QoQ) Bacchus D & F (YoY) [KRW bil.] [KRW bil., mil. bottles] Sales Bottles -0.3% 82.0 81.6 -0.3% 30.2 30.1 37.2 -9.8% 33.6 39.2% 39.2% 2.7% 32.7 2.5 3.6 5.4 7.5 Bucchus D Bucchus F Bucchus D Bucchus F 1Q '12 1Q '13 4Q '12 1Q '12 1Q '13 1Q '12 1Q '13 12
Slide 14: OTC and Major OTC Products
OTC (YoY, QoQ) Major OTC Products (YoY) [KRW bil.] [KRW bil.] -1.1% 7.3 7.2 10.6% 5.8 5.3 -18.9% 3.7 -24.0% 3.0 2.8 35.4 -2.0% 2.2 34.7 4.1% 33.3 Panpyrin Garglin Bigen Morning Care 1Q '12 1Q '13 4Q '12 1Q '12 1Q '13 13
Slide 15: IV. Current Issues
W Donc-a ST IV. CURRENT ISSUES 14
Slide 16: Trius phase III data presented at ECCMID
Trius Theraputics presented clinical data of phase III trial at ECCMID in Berlin on April 29th Proved the same efficacy with lower dosage in shorter period of time 15
Slide 17: Superior in all attributes
Superior in all attributes: simple dosage, lower resistance development, superior efficacy, effective for all patient types 16
Slide 18: 30% market share of MRSA market achievable
30% MS of total MRSA market (about $3bil.) is highly achievable 17
Slide 19: First US FDA IND approval of Korean phyto-medicine: DA-9801
The first IND application approval of a Korean phyto-medicine in the U.S. FDA DA-9801 Mixture extract of ‘Dioscorea Nipponica’ for the treatment of diabetic neuropathy Superior in pain reliving than existing drugs (peripheral nerve + central nerve) Global diabetic neuropathy market size :
Slide 20: Non-vascular stent medical equipment company and R&D products
A medical equipment company specialized in non-vascular stent Annual sales are around KRW10.0bil. (80% of total sales come from export, mainly to France, Germany, Russia and Japan) Strategic change of Dong-A ST’s Medical division from selling imported products to developing and selling our own
Slide 21: Appendix
= n < Oo z fe) a 6
Slide 22: R&D pipeline: NCE
MAJOR TYPE CODE NAME DESCRIPTION STAGE INDICATION Phase 3 completed (USA) Erectile Dysfunction Warner Chilcott Benign Prostatic Under Phase 2 (JPN) Hyperplasia Meiji Seika Pharma. DA – 8159 PDE-5 Inhibitor Under Phase 2 (EU) Portal Hypertension Dr. Falk Pulmonary Arterial Under Phase 2 (KOR) Hyperte
Slide 23: R&D pipeline: Phyto and Bio
TYPE CODE NAME MAJOR INDICATION DESCRIPTION STAGE Under Phase 2 (KOR) Phyto DA-9801 Diabetic Neuropathy Herbal Extracts Phase 2 planned (USA) Infertility DA-3801 Recombinant FSH Under Phase 3 (KOR) (Ovulation Induction) DA-3803 Infertility Recombinant hCG Under Phase 3 (KOR) DA-3030 Diabetic Neuropa
Slide 24: Thank you.
—_—__— Thank you.